In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas

Esther De Boer, Jason M. Warram, Matthew D. Tucker, Yolanda E. Hartman, Lindsay S. Moore, Johannes S. De Jong, Thomas K. Chung, Melissa L. Korb, Kurt R. Zinn, Gooitzen M. Van Dam, Eben L. Rosenthal, Margaret S. Brandwein-Gensler

Research output: Contribution to journalArticlepeer-review

55 Scopus citations


Anti-EGFR (epidermal growth factor receptor) antibody based treatment strategies have been successfully implemented in head and neck squamous cell carcinoma (HNSCC). Unfortunately, predicting an accurate and reliable therapeutic response remains a challenge on a per-patient basis. Although significant efforts have been invested in understanding EGFR-mediated changes in cell signaling related to treatment efficacy, the delivery and histological localization in (peri-)tumoral compartments of antibody-based therapeutics in human tumors is poorly understood nor ever made visible. In this first in-human study of a systemically administered near-infrared (NIR) fluorescently labeled therapeutic antibody, cetuximab-IRDye800CW (2.5â €‰mg/m 2, 25â €‰mg/m 2, and 62.5â €‰mg/m 2), we show that by optical molecular imaging (i.e. denominated as In vivo Fluorescence Immunohistochemistry) we were able to evaluate localization of fluorescently labeled cetuximab. Clearly, optical molecular imaging with fluorescently labeled antibodies correlating morphological (peri-)tumoral characteristics to levels of antibody delivery, may improve treatment paradigms based on understanding true tumoral antibody delivery.

Original languageEnglish (US)
Article number10169
JournalScientific reports
StatePublished - Jun 29 2015

All Science Journal Classification (ASJC) codes

  • General

Cite this